At 4mg weekly, each injection is approximately 1.33mg
Obesity Disease Burden and Population Health ROI Framework Economic Cost of Obesity, Comorbidity Cascade, and GLP-1 Pharmacotherapy Value-Based Evidence Reshape Global Treatment Investment The Global Obesity Forum estimated total annual economic costs of obesity at USD 4.32 trillion annually in 2025 , representing 2.92% of global GDP and exceeding the full economic output of Germany
However, a Precision Peptide Genetic Test from PlexusDx can provide context about your peptide-pathway predispositions and support a more informed conversation with your provider about expected response patterns and tolerability
However, medical professionals generally recommend baseline metabolic panels, thyroid function tests, and kidney function assessments before starting GLP-1 therapy
Semaglutide is an appetite suppressant that is primarily used to treat type 2 diabetes and obesity, as indicated, and approved by the Food and Drug Administration (FDA)
[2] Regular follow-up with healthcare providers ensures appropriate monitoring of glycemic control, weight changes, and potential adverse effects
